FNDC5 and early-onset autosomal dominant Alzheimer disease: Indeed, similar to the therapeutic repurposing of glucagon-like peptide-1 (GLP-1) mimetics and analogs [197], irisin’s ability to enhance insulin signaling suggests it could be a promising candidate for Alzheimer’s disease (AD) therapy.